4.3 Article

A 3D bioprinting exemplar of the consequences of the regulatory requirements on customized processes

Journal

REGENERATIVE MEDICINE
Volume 10, Issue 7, Pages 863-883

Publisher

FUTURE MEDICINE LTD
DOI: 10.2217/rme.15.52

Keywords

3D bioprinting; additive manufacturing; ATMP; autologous; combination; customization; EMA; personalized; regulation; US FDA; validation

Funding

  1. EPSRC
  2. Engineering and Physical Sciences Research Council [EP/K037099/1, EP/H028277/1] Funding Source: researchfish
  3. EPSRC [EP/K037099/1, EP/H028277/1] Funding Source: UKRI

Ask authors/readers for more resources

Computer-aided 3D printing approaches to the industrial production of customized 3D functional living constructs for restoration of tissue and organ function face significant regulatory challenges. Using the manufacture of a customized, 3D-bioprinted nasal implant as a well-informed but hypothetical exemplar, we examine how these products might be regulated. Existing EU and USA regulatory frameworks do not account for the differences between 3D printing and conventional manufacturing methods or the ability to create individual customized products using mechanized rather than craft approaches. Already subject to extensive regulatory control, issues related to control of the computer-aided design to manufacture process and the associated software system chain present additional scientific and regulatory challenges for manufacturers of these complex 3D-bioprinted advanced combination products.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.3
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available